Track the Companies Building the Future of Peptide Medicine.
Research peptide therapeutics, biotechnology companies, clinical trials, regulatory milestones, and investment catalysts from one intelligent platform.
Built for analysts, researchers & investors
Educational — not investment or medical advice
Watchlist snapshot
Recently updated trials
- SEP 18
ACHIEVE-4 — Orforglipron Phase III
LLY · Recruiting
- OCT 04
Oral Amycretin Phase 2 Readout
NVO · Data expected
- OCT 14
GSBR-1290 12-week WL readout
STOK · Analysis phase
450+
Peptide candidates tracked
120+
Public biotech companies
2,800+
Clinical trials indexed
Weekly
Intelligence report
Company tracker
Trending peptide biotech companies
LLY
Eli Lilly & Co.
Market cap
$680B
Focus
Orforglipron Phase III
Demonstration data
NVO
Novo Nordisk
Market cap
$412B
Focus
CagriSema · Amycretin
Demonstration data
VKTX
Viking Therapeutics
Market cap
$7.8B
Focus
VK2735 obesity trials
Demonstration data
AMGN
Amgen
Market cap
$155B
Focus
MariTide Phase II
Demonstration data
STOK
Structure Therapeutics
Market cap
$2.4B
Focus
GSBR-1290 readout
Demonstration data
ZLDPY
Zealand Pharma
Market cap
$8.1B
Focus
Petrelintide, Survodutide
Demonstration data
Catalyst calendar
Upcoming clinical-trial catalysts
Survodutide submission decision
Boehringer Ingelheim & Zealand Pharma
Oral Amycretin weight-loss data
Novo Nordisk (NVO)
GSBR-1290 12-week readout
Structure Therapeutics (STOK)
MariTide Phase II update
Amgen (AMGN)
CagriSema CV outcomes trial
Novo Nordisk (NVO)
Drug pipeline
Recently updated drug candidates
Orforglipron
Eli Lilly & Co.
- Indication
- Obesity / T2D
- Modality
- Small molecule (oral)
- Status
- Recruiting
CagriSema
Novo Nordisk
- Indication
- Weight management
- Modality
- Co-formulation
- Status
- Active
VK2735
Viking Therapeutics
- Indication
- Metabolic health
- Modality
- Dual GLP-1/GIP
- Status
- Dose escalation
MariTide
Amgen
- Indication
- Obesity
- Modality
- Peptide-antibody conjugate
- Status
- Enrolling
GSBR-1290
Structure Therapeutics
- Indication
- Obesity
- Modality
- Oral GLP-1 agonist
- Status
- Data expected
Petrelintide
Zealand Pharma
- Indication
- Obesity
- Modality
- Amylin analog
- Status
- Recruiting
Research topics
Popular peptide research topics
Workflow
How the platform works
01
Discover
Search 450+ peptide candidates, 120+ public biotech companies, and 2,800+ clinical trials with source-linked profiles.
02
Track
Build watchlists for companies, drug candidates, and catalyst events. Filter by phase, mechanism, and therapeutic area.
03
Get alerts
Receive email alerts on trial readouts, FDA decisions, earnings, partnerships, and SEC filings for anything on your watchlist.
04
Research with AI
Ask the Peptide Intelligence AI grounded questions. Every claim is cited with source and publication date.
Membership
Free vs Premium vs Professional
| Feature | Free · $0 | Premium · $29/mo | Professional · $99/mo |
|---|---|---|---|
| Peptide library access | Limited | Full | Full |
| Company tracker | Limited | Full | Full |
| Watchlists | 1 · 5 tickers | Unlimited | Unlimited |
| Catalyst calendar | Delayed | Real-time | Real-time · priority |
| AI research questions | Limited | Expanded | Highest limit |
| Weekly intelligence report | Public | Premium | Premium + team |
| Data export | — | Included | Included |
| Team workspace (up to 5) | — | — | Included |
| API access (beta) | — | — | Included |
Weekly intelligence report
Peptide biotech, delivered every Monday.
One weekly briefing: catalysts, trial readouts, regulatory moves, and pipeline updates across peptide-focused public companies. Educational — not medical or investment advice.
Medical disclaimer
Educational and research information only. No medical advice, diagnosis, prescriptions, treatment recommendations, or peptide-use instructions.
Read full policy →
Investment disclaimer
General information only. Not personalized investment advice. Biotech investing carries substantial risk, including possible loss of principal.
Read full policy →
Research disclaimer
Many peptides discussed may be investigational, unapproved, discontinued, or supported only by preliminary research. Inclusion is not endorsement.
Read full policy →
FAQ
Frequently asked questions
Does Peptide Intelligence sell peptides?+
No. We are an educational research and intelligence platform. We do not sell peptides, prescribe treatments, recommend dosages, or provide administration instructions.
Is this investment advice?+
No. All information is educational. We do not provide personalized investment advice. Biotech investing carries substantial risk, including possible loss of principal.
Where does your data come from?+
We aggregate from public sources: ClinicalTrials.gov, FDA records, SEC filings, peer-reviewed journals, company investor relations, and recognized financial data providers. Sources are cited on every record.
Is peptide use legal?+
Legal status varies by peptide, jurisdiction, and context. Many peptides discussed are investigational or unapproved. We do not advise on legality or personal use — consult qualified medical and legal professionals.
Can I cancel anytime?+
Yes. Premium and Professional plans can be cancelled anytime from your billing page. You'll retain access through the end of your billing period.
Do you have an API?+
An API is available on the Professional plan (beta). Full documentation is in development.